Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a topical treatment combining arginine and zinc significantly reduced hair loss and increased anagen hair percentage in patients with androgenetic alopecia and telogen effluvium, suggesting it might be a promising alternative to finasteride.

This study identified Azithromycin and Roxithromycin as novel senolytic antibiotics that effectively target and reduce senescent human fibroblast cells.

This study found that intralesional methotrexate and triamcinolone acetonide have similar efficacy for localized alopecia areata in adults, but differ in safety profiles, with methotrexate associated with hyperpigmentation and triamcinolone with atrophy.

In this review, the researchers discuss the potential effectiveness of azelaic acid peels for treating acne vulgaris, melasma, and other skin conditions, while acknowledging that the precise role of these peels in dermatology is not yet fully established due to limited studies.

This study reported that BRL 7660 significantly reduced sebum secretion and acne symptoms in human studies with topical administration, but the placebo effect and commercial pressures halted further investigations.

This article reviews the clinical efficacy of Ruxolitinib cream for skin conditions, reporting significant improvements in atopic dermatitis and vitiligo, with minimal systemic absorption and a favorable safety profile, compared to placebo.

This review highlights the variability and unpredictability of alopecia areata, ranging from single scalp patches to total body hair loss, and notes the 2022 approval of the first AA-specific drug, baricitinib, potentially spurring new research into targeted treatments.

This study found that Avicennia marina extract significantly increased hair growth in androgenic alopecia patients, suggesting its potential effectiveness by inhibiting 5 alpha-reductase and regulating relevant growth factors.

This study identified Saponin Re and Emodin as top candidates for treating androgenetic alopecia, suggesting future research in dermal papilla cell cultures and scalp organoids despite safety concerns.

In this retrospective study, low-dose methotrexate was observed to be effective and well-tolerated in treating recalcitrant alopecia areata multiplex, achieving complete or near-complete hair regrowth in about 90% of patients despite some experiencing elevated liver enzymes and gastrointestinal discomfort.

This article reviews topics from the American Academy of Veterinary Dermatology and American College of Veterinary Dermatology Annual Meeting and contains no new clinical findings.

This study concluded that the long-pulsed alexandrite laser is safe for hair removal in patients with Fitzpatrick skin types IV-VI, with complications occurring in only 2% of cases.

This study presents four cases of delusions of parasitosis and introduces escitalopram as a potential therapy, highlighting its fewer side effects compared to the commonly used pimozide.

This study found that a specific mutation in the mouse RXRalpha gene significantly impacts immune responses and causes hair loss and skin cysts.

This phase 2a trial evaluated Samcyprone for common wart treatment and found that while a sensitization reaction is necessary for therapeutic response, its level does not predict wart clearance.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This study observed that the ethyl acetate extract of Equisetum debile showed high activity against 5α-reductase and lipid peroxidation with no cytotoxicity on dermal papilla cells.

This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.

Dermoscopy quickly and accurately diagnosed a rare hair disorder in a 12-year-old girl.

In this case report, a 14-year-old girl developed azathioprine-induced anagen effluvium, highlighting it as a rare but reversible side effect with prompt drug withdrawal leading to significant hair regrowth.

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

This quiz presents educational questions about alopecia areata, including its diagnosis and underlying mechanisms, but reports no new clinical outcomes.

Alopecia areata treatments often cause headaches and infections, highlighting the need for safer options.

In this case series, cats infested with Lynxacarus radovskyi developed self-induced alopecia similar to flea allergic dermatitis, primarily affecting the perianal area.

This study found that supplementing with 1.5% α-ketoglutaric acid significantly improved the performance, hair follicle density, and antioxidant capacity in Rex rabbits, potentially by enhancing the Wnt signaling pathway and reducing amino acid catabolism.

This report describes a 7-year-old girl with monilethrix who showed significant improvement while on acitretin treatment, but symptoms returned after stopping the medication.

In this study, distinct molecular mechanisms of action were identified for three drugs used in alopecia areata clinical trials, providing insights for precision medicine and treatment selection.

This study found that a transdermal delivery system using 3% azone and P407 gel may enhance the skin permeation of doxazosin and finasteride for treating benign prostatic hyperplasia.